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ABSTRACT
The antitumor drug taxol was metabolized to one major (6a-
hydroxytaxol) and two minor metabolites by human liver micro-
somes. A 1 0-fold intehndividual variability with a V of 1 .1 6 ±
0.85 nmol/hr/mg of microsomal protein and a Km of 18.0 ± 12.2
M was observed for taxol 6a-hydroxylation (mean ± S.D.; n =
6). The NADPH-dependency and the inhibitory effect of carbon
monoxide and piperonyl butoxide on taxol metabolism indicated
the Involvement of cytochrome P450 (CYP) monooxygenases.
Chemical inhibition studies pointed to the CYP 3A subfamily as
being responsible for taxol 6a-hydroxylatlon. However, although
some CYP 3A substrates were inhibitory(midazolam, I 7a-ethinyl
estradlol, quercetin, verapamil and testosterone), others were
not (troleandomycin, erythromycin and cyclosporin A). The inhi-
bition was found to be competitive with low K, values for mida-
zolam (1 0.5 M) and I 7a-ethinyl estradiol (4.5 SM). Taxol 6a-
hydroxylation correlated well with the metabolism of 1 7a-ethinyl
estradiol (r = 0.874; P < .05) and midazolam (r = 0.954; P <
.01) in the same livers. Rabbit anti-rat CYP 3A1 antibodies, which
cross-react with human CYP 3A isoforms, were inhibitory of
taxol 6cr-hydroxylation. Although the evidence from these exper-
iments supported the CYP 3A mediation of taxol 6a-hydroxyl-
atlon, the lack of effect of some inhibitors combined with the
inability of a human CYP 3A4 transfected cell line to metabolize
taxol point to a CYP 3A isoform other than 3A4. The findings in
this study could prove dinically useful for the prediction of
potential drug interactions, both inhibitory and inductive of taxol
metabolism.
Taxol (Paclitaxel), an antitumor drug obtained from the
Pacific yew tree (Taxus brevifolia), has been demonstrated to
be active against drug-refractory ovarian and breast cancers as
well as malignant melanoma (Rowinsky et ci, 1990) with dose-
limiting neurological side effects (Lipton et aL, 1989). It appears
to act by interfering with the tubulin-microtubule system (Hor-
witz, 1992). The biological fate of taxol is not well understood.
In phase I clinical trials, less than 10% of the dose was excreted
unchanged in urine (Wiernik et at., 1987), whereas another
20% was detected in bile (Wright et aL, 1992). The remaining
70% may likely be metabolites appearing in the bile and feces.
We have recently isolated and characterized the major metab-
olite of taxol, 6a-hydroxytaxol (fig. 1) (Kumar et at., 1994), in
human liver microsomes, a metabolite distinctly different from
the two known metabolites in the rat (fig. 1) (Monsarrat et at.,
1990; Walle et at., 1993). 6a-Hydroxytaxol has also been pro-
posed as the major in vivo metabolite of taxol in humans
(Wright et aL, 1992). Like other anticancer agents, taxol has a
narrow therapeutic window. Any factor that alters its disposi-
tion is likely to have an effect on the therapeutic/toxicological
outcome of taxol therapy. Inhibition or induction of its metab-
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olism or potential genetic polymorphism in the drug-metaboliz-
ing enzymes involved could be of clinical significance. In this
study we have demonstrated the predominant role of CYP 3A
in the human liver microsomal metabolism of taxol to its major
metabolite, 6a-hydroxytaxol.
Materials and Methods
Materials. Human livers were obtained from the Liver Tissue
Procurement and Distribution System (University of Minnesota, Mis-
neapolis, MN). The cause of death was either cerebral hemorrhage or
head trauma. The livers were flash frozen and stored at -80#{176}C.Taxol
(Calbiochem, San Diego, CA); [3Hjtaxol (specific activity, 17-23 Cu
mmol; radiochemical purity, 99.9%; Moravek Biochemicals, Brea, CA);
17a-ethinyl estradiol, tolbutamide, benzphetamine, phenacetin, tro-
leandomycin, testosterone, quercetin and NADP (Sigma Chemical Co.,
St. Louis, MO); p-nitrophenol and aniline (Aldrich Chemical Co.,
Milwaukee, WI); sparteine, coumarin and erythromycin (Fluka Chem-
ical Corp., Ronkonkoma, NY); cyclosporine A (Sandoz Ltd., Basel,
Switzerland); verapainil (Knoll Pharmaceuticals, Whippany, NJ); mid-
azolam (Hoffmann-La Roche, Nutley, NJ); and 6g3- and 11-hydroxy-
testosterone (Steraloids Inc., Wilton, NH) were used in the study.
Other chemicals used were of reagent grade. AHH-1 TK+/- human B-
lymphoblastoid cells transfected with 1-histidinol-resistant vector
(cHol, control cells) or vector with human CYP 3A4 eDNA (h3A4 v3)
were obtained from Gentest Corporation (Woburn, MA). Rabbit poly-
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Fig. 1. Structures of taxol, 6a-hydroxytaxol and two known rat metab-
olites (RM1 and RM2). All mets/pare-aromatic protons as well as the 2-,
10- and 3’-protons were tritlum labeled in the rH)taxol used.
clonal anti-rat CYP 3A1 antiserum and preimmune serum were ob-
talned from Human Biologics Inc. (Phoenix, AZ) (Parkinson and
Gemzth, 1991).
Incubation. Human liver microsomes were prepared by differential
centrifugatuon (Jurima et aL, 1985) and were stored at -80CC until use.
Protein concentration was determined according to Lowry et al., (1951)
using bovine serum albumin as the standard. Preliminary experiments
established the optimal conditions of incubation with respect to time
of incubation and protein concentration. The taxol metabolism was
found to be linear between 0.2 and 2.0 mg of microsomal protein per
ml and up to 40 mm. The incubation system consisted of 1 mg/mi of
microsomai protein in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid buffer (0.05 M, pH 7.4) and an NADPH-generating system (2 mM
MgCl2, 0.4 mM NADP, 4 mM glucose 6-phosphate and 0.2 U of glucose
6-phosphate dehydrogenase; Jurima et aL, 1985). The reaction was
started by the addition of taxol stock solution in dimethylsulfoxide
containing [3H)taxol (0.5 iCi/ml of incubate). The final concentration
of dimethylsulfoxide was 0.2% v/v; 0.3% with inhibitors present. This
concentration has no effect on CYP-mediated metabolism (Steiner and
Walle, 1992). The incubation was conducted at 37#{176}Cfor 20 mm in a
shaking water bath. The reaction was stopped by rapid cooling in ice,
followed by extraction of taxol and its metabolites into five volumes of
ethyl acetate (extraction efficiency > 90%). The ethyl acetate layer was
separated and evaporated under nitrogen. The residue was reconsti-
tuted in HPLC mobile phase for further analysis.
HPLC analysis. The HPLC system consisted of a Waters model
510 pump (Bedford MA), a Waters U6K injector, a reversed-phase
Curosil G 6 sm (250 x 3.2 mm) column (Phenomenex, Torrance, CA)
with a guard column, a Waters model 440 UV detector with a 229 nm
filter, a Kipp & Zonen chart recorder (Curtis Matheson Scientific,
Houston, TX) and a RediFrac fraction collector (Pharmacia, Piscata-
way, NJ). The mobile phase consisted of 35% acetomtrile in water.
The flow rate was 0.6 ni/mis. The retention times for taxol and 6a-
hydroxytaxol were 60 and 37 miii, respectively. The metabolite quan-
titation was done by liquid scintillation spectrometry of the HPLC
eluate corresponding to the metabolite.
Kinetics. The kinetic characterization of taxol 6a-hydroxylation in
six individual human liver microsomal preparations was done as de-
scribed above using 5 to 67 M taxol (six concentrations). The apparent
Vmsz and K,,, values were calculated from the Lineweaver-Burk plots.
The highest activity was found with liver UM 208. Hence the inhibition
experiments were done with this liver.
Chemical inhibition. The incubation system and conditions were
as described above. The final concentrations of taxol and the inhibitor
were 10 and 50 M, respectively. With erythromycin, cyclosporin A
and troleandomycin, experiments were also conducted at an inhibitor
concentration of 100 aiM. The inhibition experiments with midazolam
and 17a-ethinyl estradiol were done with a range of concentrations (0-
40 M) to generate Dixon plots. The inhibitor was added to the
incubation system immediately before the addition of taxol. With
carbon monoxide, the gas was bubbled through the incubate for 30 sec
immediately before the start of incubation and the tube was capped
tightly. In the case of troleandomycin, the inhibitor, microsomes and
NADPH-generating system were preincubated at 37CC for 20 mm
before the addition oftaxol. An appropriate control experiment without
troleandomycmn was done in parallel.
Correlation studies. The metabolism of taxol (30 sm), midazolam
(60 M) and 17a-ethinyl estradiol (50 M) was studied under identical
conditions in the six individual human liver microsomai preparations.
Previously published methods were used for the assay of 2-hydroxy-
17a-ethinyl estradiol (Guengerich, 1988) and 1’- and 4-hydroxymida-
zolam (Kronbach et cii., 1989).
Immunoinbibition. A mixture of 20 ig of microsomal protein and
varying amounts of preimmune or 3A antiserum was kept at 23CC for
20 mm. Then taxol (final concentration, 1 M) spiked with [3Hjtaxol
and an NADPH-generating system were added and incubated at 37#{176}C
for 20 mm. The extraction and analysis were as described above.
Taxol metabolism in a CYP 3A4 cell line. The control (cHol)
and 3A4 transfected cell line (h3A4 v3) were propagated in Roswell
Park Memorial Institute Medium 1640 without histidine and supple-
mented with horse serum to 9% v/v and 2 mM l-histidinol. The
testosterone 69-hydroxylase activity was used as a positive control. For
the assay, 20 x 10 cells were lysed in 0.5 ml of water. Then 0.5 ml of
0.1 M phosphate buffer (pH 7.4) containing an NADPH-generating
system and either taxol (2 MM with 0.25 zCi of [3Hjtaxol) or testoster-
one (400 zM) was added to the lysed cells. For inhibition studies, a
final concentration of 50 M of inhibitor was used. The incubation was
done at 37#{176}Cfor 1 hr. The extraction and analysis of taxol and its
metabolites were done as above. 113-Hydroxytestosterone was used as
an internal standard for testosterone analysis. Testosterone and its
metabolites were extracted into five volumes of methylene chloride,
which was evaporated and the residue was dissolved in HPLC mobile
phase for further analysis. A Nucleosil C1s column (Phenomenex) with
UV detection at 254 nm was used for HPLC analysis. The mobile phase
consisted of 63% v/v methanol-water at a flow rate of 0.9 ml/min. The
quantitation of 6-hydroxytestosterone was done by comparing HPLC
peak heights to those of an authentic standard.
Statistics. All values are expressed as the means ± S.D. Two-tailed
Student’s t-test for paired data was performed to calculate P values; P
< .05 was considered significant.
Results
Kinetics of Oa-hydroxytaxol formation. Taxol was me-
tabolized by human liver microsomes to one major (6a-hydrox-
ytaxol; Kumar et aL, 1994) and two minor metabolites, the
latter two not yet identified. The metabolic profile was quali-
tatively the same in all six livers investigated. Due to the low
rates of formation of the minor metabolites, clear data could
not be obtained for these metabolites. The formation of 6a-
hydroxytaxol exhibited monophasic Michaelis-Menten kinet-
ics. The mean apparent V value was 1.16 ± 0.85 nmol/hr/
mg of microsomal protein and the Km value was 18.0 ± 12.2
M (table 1). The in vitro intrinsic clearance (Cl = Vmax/Km)
(Wilkinson, 1987) was calculated to be 0.089 ± 0.075 mi/hr/mg
of microsomal protein. A very large, 10-fold, variability in the
VmAz and Cl10 values in the six liver preparations was observed.
Some of this variability may be sex-dependent. Thus, the V
values, and in particular the CL values, were as much as 6
times higher in the livers obtained from the female than the
male donors.
Chemical inhibition. Taxol 6a-hydroxylation was found to
be NADPH-dependent. Both carbon monoxide (which binds to
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TABLE 1
Taxol 6a-hydroxylation by human liver microsomes








UM592 10 M 0.78 22.1 0.035
UM505 23 M 0.87 18.8 0.046
UM256 51 M 0.88 39.7 0.022
UM 208 16 F 2.67 12.5 0.214
UM312 22 F 1.55 8.4 0.185
UM 350 25 M 0.22 6.6 0.033
Mean 1.16 18.0 0.089





Fig. 2. Inhibition of taxol (1 0 M) metabolism by CYP 3A substrates (50
MM). Mean values ± S.D. of three determinations are shown. #{176}P< .001;
#{176}#{176}P< .005. Control activity was 1 .98 nmol/hr/mg of microsomal protein.
inhibitor of CYP) were found to inhibit 94 and 74% of taxol
6a-hydroxylation, respectively, indicating the involvement of
CYP in taxol 6a-hydroxylation. The potential inhibition of
taxol 6a-hydroxylation by substrates selective for the isoforms
of CYP most capable of mediating drug metabolism (Wrighton
and Stevens, 1992) was tested in liver UM 208 with a taxol
concentration of 10 M. Whereas 17a-ethinyl estradiol (50
SM), a substrate for CYP 3A (Guengerich, 1988) was found to
be inhibitory (81% inhibition of control activity), other CYP
substrates (also at 50 zM) were not inhibitory [phenacetin,
1A2, 4% (Gonzalez, 1992); coumarin, 2A6, 0% (Gonzalez, 1992);
benzphetamine, 2B, 6% (Riley et at., 1993); tolbutamide, 2C,
0% (Gonzalez, 1992); sparteine, 2D6, 7% (Gonzalez, 1992);
aniline, 2E, 2% (Nakura et al., 1992); and p-nitrophenol, 2E,
21% (Riley et a!., 1993)]. The susceptibility of taxol 6a-hydrox-
ylation to inhibition by 17a-ethinyl estradiol (50 zM) was
tested in all six livers. The inhibition was found to be 72.5 ±
7.6% (P < .001). These observations pointed to the possibility
of CYP 3A subfamily involvement in taxol 6a-hydroxylation.
To gain further support for this notion, the inhibition of taxol
6a-hydroxylation was determined with several known sub-
strates of CYP 3A (fig. 2). In addition to 17a-ethinyl estradiol
(Guengerich, 1988), midazolam (Kronbach et al., 1989), verap-
amil (Kroemer et al., 1992), testosterone (Gonzalez, 1992) and
quercetin (Miniscalco et al., 1992) were found to be inhibitory,
whereas other CYP 3A substrates, viz. erythromycin (Watkins
et at., 1989), cyclosporin A (Kronbach et at., 1988) and trolean-
domycin (Pessayre et a!., 1983) were not inhibitory even at a
higher concentration (100 SM).
The nature of inhibition was studied using midazolam and
17a-ethinyl estradiol in various concentrations. The inhibition
was found to be competitive in both cases, as clearly depicted
by the Dixon plots (fig. 3). The K values for midazolam and
17a-ethinyl estradiol were 10.5 and 4.5 M, respectively.
Correlation studies. The taxol 6a-hydroxylation in six
liver preparations was correlated with the metabolism of mid-
azolam to its 1’- and 4-hydroxy metabolites and l7cr-ethinyl
estradiol to its 2-hydroxy metabolite (fig. 4). The experiments
were done in parallel under identical conditions so as to mini-
mize experimental variability. The metabolism of taxol and
l7cr-ethinyl estradiol correlated well with a linear regression
coefficient (r) of 0.874 (P < .05) and a Spearman rank corre-
lation coefficient (r,) of 0.886 (P < .05). The metabolism of
taxol and midazolam correlated well with an r of 0.954 (P <
.01). The Spearman rank correlation coefficient (r,) had a value
of 0.829 which did not quite reach significance (P < .1). The
activity levels of midazolam 1 ‘ - and 4-hydroxylation (Kronbach
et al., 1989) and 17c-ethinyl estradiol 2-hydroxylation (Purba
et aL, 1987) obtained in this study compared well with previ-
ously reported values.
Immunoinhibition. The anti-rat 3A1 rabbit antiserum in-
hibited Ga-hydroxytaxol formation in a dose-dependent fashion
(fig. 5). This inhibition was significant compared to preimmune
serum (fig. 5) at antibody concentrations  4 mg of immuno-
globulin G/mg of microsomal protein. The maximum inhibition
achieved was 65%.
100 Taxol metabolism in a CYP 3A4 cell line. The 3A4 cell
line (h3A4 v3) exhibited a 10-fold higher testosterone 6/3-
hydroxylase activity (5 pmol/min/106 cells) compared to the
control cell line (0.5 pmol/min/106 cells). More than 80% of
the testosterone 6/3-hydroxylase activity in the 3A4 cell line
was inhibited by midazolam (50 tM), whereas the residual
testosterone 6/3-hydroxylase activity in the control cell line was
not inhibited by midazolam. Both control and 3A4 cell lines
exhibited very low taxol 6a-hydroxylation (0.005 ± 0.001 pmol/
min/106 control cells and 0.007 ± 0.002 pmol/min/106 3A4
cells; n = 3; not significantly different), which is approximately
1/50th of human liver microsomal taxol 6a-hydroxylation ac-
tivity based on milligram of protein. Furthermore, neither
midazolam (50 M) nor 17a-ethinyl estradiol (50 m) inhibited
taxol 6a-hydroxylation activity in control or 3A4 cell lines.
Discussion
The metabolism of taxol in human liver microsomes is both
regiospecific and stereospecific, leading to the formation of 6cr-
hydroxytaxol (Kumar et aL, 1994). The monophasic Michaelis-
Menten kinetics observed indicated the involvement of a single
enzyme system. The NADPH-dependency of the metabolism
and the inhibitory effect of carbon monoxide and piperonyl
butoxide implicated the CYP group of monooxygenases in taxol
6a-hydroxylation. Chemical inhibition studies were used to
identify initially the CYP isoform(s) responsible for taxol 6cr-
hydroxylation. None to very weak inhibition by all CYP sub-
strates except l7ce-ethinyl estradiol pointed to the involvement
of the CYP 3A subfamily. When taxol 6cr-hydroxylation was
examined in the presence of other CYP 3A substrates, variable
results were obtained. Although some substrates were inhibi-
tory, others were not. Verapamil, testosterone, midazolam and
in particular quercetin were potent inhibitors. However, tro-
leandomycin, erythromycin and cyclosporine A, although con-
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Fig. 5. lnhlblon of taxol (1 atM) metaboNsm by rabbft and-rat 3A1
anserum (dosed des) and rabbft prenmune serum (open des).
Mean values ± S.D. of three determinations are shown. #{176}P< .05; #{176}P<
.02; #{176}#{176}#{176}P< .01 . Control acfivlty was 0.84 nmol/hr/mg of microsomal
protein. IgG, lmmunoglobuhn G.
sidered typical CYP 3A substrates (Murray and Reidy, 1990),
were not inhibitory of taxol 6a-hydroxylation even at rather
high concentrations (100 &M). Troleandomycin has been shown
previously to be a weak inhibitor of the metabolism of several
other CYP 3A substrates such as dapsone (Fleming et aL, 1992),
Fig. 3. Dixon plots for the inhibi-
tion of taxol metabolism by 17cr-
ethinyl estradiol (left) and midazo-




Fig. 4. CorrelatIon of taxol (30
MM) metabolism with the me-
tabolism of 17cr-ethinyl estra-
d (50 M) (left) and midazo-
lam (60 MM) (right).
terfenadine (Yun et aL, 1993) and 4,4’-methylene-bis[2-chlo-
roaniline] (Yun et aL, 1992), and cyclosporin A was a rather
poor inhibitor of another 3A substrate, vindesine (Zhou et aL,
1993). In in uwo studies the erythromycin N-demethylase ac-
tivity (a marker for CYP 3A expression) was found not to
correlate with the in vivo metabolism of alfentanil (Krivoruk
et at., 1993) and cortisol (Hunt et aL, 1992), both CYP 3A
substrates. It is therefore not unexpected that some of the
“known” CYP 3A substrates were not inhibitory of taxol me-
taboism. The inhibition by midazolam and 17a-ethinyl estra-
diol was found to be competitive. The K, values for both of
these substrates were low with the potential for clinical inter-
action with taxol.
The in vitro metabolic correlations between taxol hydroxyl-
ation and 17a-ethinyl estradiol or midazolam hydroxylation
obtained in this study compare favorably with the correlations
reported for other CYP 3A substrates (CQA 206-291 vs. mida-
zolam, Ball et aL, 1992; terfenadine vs. nifedepine, Yun et aL,
1993; and dapsone vs. nifedipine, fleming et aL, 1992). These
positive correlations offer further support for the CYP 3A
mediation of taxol 6cs-hydroxylation.
A more definitive support for CYP 3A mediation of taxol
metabolism was obtained with the use of anti-rat CYP 3A1
rabbit polyclonal antibodies which cross-react with human
CYP 3A isoforms. These antibodies have been reported to be
inhibitory of CYP 3A-mediated metabolism such as tamoxifen
N-demethylation (Mani et aL, 1993) and testosterone 6-hy-
droxylation (Eberhart et aL, 1991). The concentration-depend-
1164 Kumaretal. Vol. 268
ent inhibition of taxol 6a-hydroxylation further confirmed the
CYP 3A mediation.
The genetically engineered human CYP 3A4 cell line as
expected was found to be active in the 6/3-hydroxylation of
testosterone, the prototype 3A4 substrate. Only trace amounts
of 6a-hydroxytaxol were, however, formed and the activity of
the 3A4 cell line did not differ from that of the control cell line.
Even the testosterone 6-hydroxylation was only 4% of the
reported human microsomal testosterone 6/3-hydroxylation ac-
tivity (Mani et at., 1993). The low taxol 6a-hydroxylase activity
in the 3A4 cell line could therefore be due either to the low
expression of CYP 3A4 or more likely to a negligible contribu-
tion of this 3A isoform to the 6a-hydroxylation of taxol.
From the chemical inhibition, metabolic correlation and im-
munoinhibition studies, it can be concluded that taxol 6cr-
hydroxylation is catalyzed predominantly by the CYP 3A
subfamily of monooxygenases. The 3A subfamily enzymes are
the most predominant group of CYP enzymes in the human
liver (Gonzalez, 1992) with at least four known isoforms [3A3,
3A4, 3A5 and 3A7 (fetal)]. From the present data, it is not
possible to pinpoint the contribution of the individual isoforms
of CYP 3A. One of the CYP 3A isoforms, 3A5, has been shown
to have somewhat different though overlapping substrate spec-
ificity from that of CYP 3A4 (Aoyama et at., 1989; Wrighton et
aL, 1990). With midazolam, livers expressing a polymorphic
CYP 3A isoform (possibly 3A5) along with the predominant
3A4 have been reported to have higher activity than livers
expressing 3A4 alone (Kronbach et at., 1989). The role of each
isoform of the CYP 3A subfamily in taxol 6cr-hydroxylation
thus needs to be explored further.
As already pointed out (fig. 1), taxol metabolism in the rat
produces two main metabolites (Monsarrat et aL, 1990, Wale
et aL, 1993), which are distinctly different from the major
human metabolite. This could imply the involvement of dis-
tinctly different CYP isoforms. However, the fact that mida-
zolain and verapamil inhibit taxol metabolism in both rats
(Wale et aL, 1993) and humans, with midazolam somewhat
more potent than verapamil, indicates that all three taxol
metaboites are derived from the CYP 3A subfamily.
The taxol 6cr-hydroxylation by human liver microsomes
showed large interindividual variation. A 10-fold variability
between the highest and lowest metabolic rates was observed
in the six livers studied. This is similar to the interindividual
variation in taxol pharmacokinetics observed in cancer patients
(Rowinsky et aL, 1990; Brown et at., 1991; Wiernik et aL, 1987).
Comparable interindividual variation has also been seen in the
human liver microsomal metabolism of several other CYP 3A
substrates such as midazolam (Kronbach et aL, 1989), terfena-
dine (Yun et aL, 1993), vindesine (Zhou et aL, 1993) and
zonisamide (Nakasa et aL, 1993). Some of this variability may
be due to genetic factors; e.g., one ofthe CYP 3A isoforms, 3A5,
is polymorphically expressed (in about 30% of individuals)
(Wrighton et at., 1990). Our preliminary observations suggest
that there may also be sex differences in the expression of some
members of this subfamily in humans as in the rat (Gonzalez
et aL, 1986). There is great potential for the alteration of taxol
disposition by coadininistered drugs or food products, which
are either CYP 3A inducers (glucocorticoids such as dexameth-
asone, phenobarbital or rifampicin) or competing CYP 3A
substrates (e.g., verapamil, midazolam, 17cr-ethinyl estradiol or
quercetin) and possibly other drugs not yet investigated (e.g.,
gestodene, tamoxifen, nifedepine, vindesine, quinidine or zon-
isamide). Ofthese drugs, verapamil, to minimize drug resistance
produced by P-glycoprotein, dexamethasone, as a premedica-
tion in taxol therapy to prevent hypersensitivity reactions
(Weiss et at., 1990) and probably quercetin, a flavonoid ingre-
dient of grapefruit juice (Miniscalco et at., 1992), are already
used together with taxol.
In conclusion, we have shown that the CYP 3A subfamily of
enzymes catalyze the biotransformation of taxol to its major
metabolite 6cr-hydroxytaxol, although the specific isoform in-
volved has yet to be determined. Many coadministered drugs
or food products are likely to modulate the activity or expres-
sion of these enzymes and are therefore likely to alter the
disposition and actions of taxol. The in vitro approach pre-
sented here should be useful for further studies of potential
drug and other interactions with taxol.
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